Critical Period for a Teratogenic VLA-4 Antagonist: Developmental Effects and Comparison of Embryo Drug Concentrations of Teratogenic and Non-Teratogenic VLA-4 Antagonists

Birth Defects Research Part B - Developmental and Reproductive Toxicology

Volumn 71, Issue 2, 2004, Pages 69-79

  Crofts, Frances ^a   Rohatagi, S ^b   Pino, M ^a   DeLise, Betty ^a,d   Zhang, J ^b   Nguyen, M ^b   Guittin, P ^a   Barbellion, S ^a   Brunel, P ^a   Hofmann, T ^a   Schmidt, J ^a   Wong, M ^c   Lockey, P ^c   Lerman, Steven ^a,e   Clark, Robert ^a,e  

^a SANOFI   (France)

^b SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^c Argenta Discovery Ltd   (United Kingdom)

^d Quality Assurance Group   (United States)

^e GLAXOSMITHKLINE   (United States)

Author keywords

Developmental toxicity; DR50; Embryo drug concentrations; Rabbit; Rat; Teratology; VLA 4 antagonist

Indexed keywords

HMR 1031; IVL 745; IVL 984; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 4; VERY LATE ACTIVATION ANTIGEN 4 ANTAGONIST;

ANIMAL MODEL; AORTA ANOMALY; ARTICLE; BONE MALFORMATION; CELL ADHESION; CONGENITAL HEART MALFORMATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; EMBRYO; EMBRYOTOXICITY; HUMAN; HUMAN CELL; MATERNAL PLASMA; NONHUMAN; PREGNANCY; PRIORITY JOURNAL; RABBIT; RAT; SPECIES DIFFERENCE; TERATOGENICITY; TERATOLOGY; TOXICITY TESTING; TOXICOKINETICS;

ABNORMALITIES, DRUG-INDUCED; ANIMALS; AORTA; AREA UNDER CURVE; CELL ADHESION; CELL LINE; CHORION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOXICITY; EMBRYO; EMBRYONIC DEVELOPMENT; FEMALE; HEART; HUMANS; IMIDAZOLES; INHIBITORY CONCENTRATION 50; INTEGRIN ALPHA4BETA1; MATERNAL EXPOSURE; MATERNAL-FETAL EXCHANGE; MODELS, CHEMICAL; PHENYLALANINE; PHENYLUREA COMPOUNDS; PREGNANCY; PREGNANCY, ANIMAL; PROPIONIC ACIDS; PROTEIN BINDING; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, VERY LATE ANTIGEN; SPECIES SPECIFICITY; TERATOGENS; TIME FACTORS;

ANIMALIA; ORYCTOLAGUS CUNICULUS;

EID: 2342637793     PISSN: 15429733     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdrb.20000     Document Type: Article

References (21)

1. Arafa HM, Elmazar MM, Hamada FM, Reichert U, Shroot B, Nau H. 2000. Selective agonists of retinoic acid receptors: comparative toxicokinetics and embryonic exposure. Arch Toxicol 73:547-556.
2. Beck F. 1981. Comparative placental morphology and function. In: Kimmel CA, Buelke-Sam J, editors. Developmental toxicology. New York, Raven Press. p 35-54.
3. Bowen JA, Hunt JS. 2000. The role of integrins in reproduction. Proc Soc Exp Biol Med 223:331-343.
4. Chen LL, Whitty A, Lobb RR, Adams SP, Pepinsky RB. 1999. Multiple activation states of integrin α4β1 detected through their different affinities for a small molecule ligand. J Biol Chem 274:13167-13175.
5. Collins MD, Tzimas G, Burgin H, Hummler H, Nau H. 1995. Single versus multiple dose administration of all-trans-retinoic acid during organogenesis: differential metabolism and transplacental kinetics in rat and rabbit. Toxicol Appl Pharmacol 130:9-18.
6. Crofts FG, Pino MV, DeLise BD, Guittin P, Barbellion S, Brunel P, Potdevin S, Bergmann B, Hofmann T, Lerman S, Clark RL. 2004. Different embryo-fetal toxicity effects for three VLA-4 antagonists. Birth Defects Res B 71:55-68 (this issue).
7. Damsky CH, Schick SF, Klimanskaya I, Stephens L, Zhou Y, Fisher S. 1997. Adhesive interactions in peri-implantation morphogenesis and placentation. Reprod Toxicol 11:367-375.
8. Dawson AB. 1926. A note on the staining of the skeleton of cleared specimens with Alizarin Red S. Stain Tech 1:123-124.
9. Derendorf H, Hochhaus G. 1995. Handbook of pharmacokinetic/pharmacodynamic correlation. Boca Raton: CRC Press.
10. Derendorf H, Hochhaus G, Mollmann H, Barth J, Krieg M, Tunn S, Mollmann C. 1993. Receptor-based pharmacokinetic-pharmacodynamic analysis of corticosteroids. J Clin Pharmacol 33:115-123.
11. Gurtner GC, Davis V, Li H, McCoy MJ, Sharpe A, Cybulsky MI. 1995. Targeted disruption of the murine VCAM-1 gene: essential role of VCAM-1 in chorioallantoic fusion and placentation. Genes Dev 9:1-14.
12. Hays SM, Elswick BA, Blumenthal GM, Welsch F, Conolly RB, Gargas ML. 2000. Development of a physiologically based pharmacokinetic model of 2-methoxyethanol and 2-methoxyacetic acid disposition in pregnant rats. Toxicol Appl Pharmacol 163:67-74.
13. Hoar RM, Monie IW. 1981. Comparative development of specific organ systems. In: Kimmel CA, Buelke-Sam J, editors. Developmental Toxicology. New York: Raven Press. p 13-33.
14. Hutson MR, Kirby ML. 2003. Neural crest and cardiac development: a 20-year perspective. Birth Defects Res Part C Embryo Today 69:2-13.
15. Mantel N, Haenszel W. 1959. Statistical aspects of the analysis of data from retrospective studies of disease. JNCI 22:719-748.
16. Rossant J, Croy BA. 1985. Genetic identification of tissue of origin of cellular populations within the mouse placenta. J Embryol Exp Morphol 86:177-189.
17. Salewski (Koeln) V.E. 1964. Faerbermethode zum makroskopischen nachweis von implantations stellen am uterus der ratte. NaunynSchmeidebergs Archiv fur Pharmakologie und Experimentelle Pathologie 247:367.
18. Shepard TH. 1986. Catalog of teratogenic agents. 5th edition. Baltimore: Johns Hopkins University Press.
19. Sheppard AM, Onken MD, Rosen GD, Noakes PG, Dean DC. 1994. Expanding roles for α-4 and its ligands in development. Cell Adhesion Commun 1:27-43.
20. Spence S, Vetter C, Hagmann WK, Van Riper G, Williams H, Mumford RA, Lanza TJ, Lin LS, Schmidt JA. 2002. Effects of VLA-4 antagonists in rat whole embryo culture. Teratology 65:26-37.
21. Yang JT, Rayburn H, Hynes RO. 1995. Cell adhesion events mediated by 4 integrins are essential in placental and cardiac development. Development 121:549-560.